Multitarget therapy with a corticosteroid, cyclosporine and mycophenolate mofetil for idiopathic membranous nephropathy: a prospective randomized controlled trial
Nephrology Dialysis Transplantation · 2023
DOI: 10.1093/ndt/gfad156 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nephrology Dialysis Transplantation, 2023. Verfasst von Yajuan Duan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Cyclosporine, Glomerulonephritis, Membranous. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Beijing Municipal Administration of Hospitals Incubating Program, Capital Medical University.
Abstract (Originalsprache)
Background
The effectiveness of multitarget combination therapy with a corticosteroid, cyclosporine and mycophenolate mofetil for idiopathic membranous nephropathy (IMN) is unclear. In the present study, we aimed to compare the efficacy and safety of multitarget therapy with a cyclical corticosteroid–cyclophosphamide regimen in patients with IMN.
Methods
This was a single-centre, prospective, randomized, controlled trial. We randomly assigned patients with IMN to receive multitarget therapy (a combination of prednisone, cyclosporine and mycophenolate mofetil) or 6-month cyclical treatment with a corticosteroid and cyclophosphamide. The study patients were followed up for 12 months. The primary outcome was a composite of complete or partial remissions at 12 months. Adverse events were also assessed.
Results
The study cohort comprised 78 patients, 39 of whom received multitarget therapy and the other 39 cyclical alternating treatment with a corticosteroid and cyclophosphamide. At 12 months, 31 of 39 patients (79%) in the multitarget therapy group and 34 of 39 (87%) in the corticosteroid–cyclophosphamide group had achieved complete or partial remissions (relative risk 0.93; 95% confidence interval 0.72–1.21; P = .85; log-rank test). The prevalence of adverse events was significantly lower in the multitarget therapy group than in the corticosteroid–cyclophosphamide group [46% (18 of 39) vs 74% (29 of 39); P < .05].
Conclusions
Multitarget therapy for IMN patients is noninferior to cyclical alternating treatment with corticosteroid and cyclophosphamide in inducing proteinuria remission and has a better safety profile than the corticosteroid–cyclophosphamide combination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Zongli Diao
Förderung
- Beijing Municipal Administration of Hospitals Incubating Program
- Capital Medical University
Zitieren
APA
Duan, Y., Bai, Y., Guo, W., Wang, L., Dai, W., Guo, W., Huang, H., Liu, W., & Diao, Z. (2023). Multitarget therapy with a corticosteroid, cyclosporine and mycophenolate mofetil for idiopathic membranous nephropathy: a prospective randomized controlled trial. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfad156
Vancouver
Duan Y, Bai Y, Guo W, Wang L, Dai W, Guo W, et al. Multitarget therapy with a corticosteroid, cyclosporine and mycophenolate mofetil for idiopathic membranous nephropathy: a prospective randomized controlled trial. Nephrology Dialysis Transplantation. 2023. doi:10.1093/ndt/gfad156
BibTeX
@article{Duan2023,
author = {Duan, Yajuan and Bai, Yu and Guo, Weikang and Wang, Liyan and Dai, Wendi and Guo, Wang and Huang, Hongdong and Liu, Wenhu and Diao, Zongli},
title = {Multitarget therapy with a corticosteroid, cyclosporine and mycophenolate mofetil for idiopathic membranous nephropathy: a prospective randomized controlled trial},
journal = {Nephrology Dialysis Transplantation},
year = {2023},
doi = {10.1093/ndt/gfad156}
}
EUVIMED